Moreover, weekly IL-17A intraperitoneal injections for 35 days induced peritoneal fibrosis characterized by PM thickness associated with fibronectin deposition and expression of myofibroblast markers, such as fibroblast-specific protein 1 (FSP-1) and α-smooth muscle actin (α-SMA) [35]. This evidence concerns the gene FN1 and Peritoneal Fibrosis.